Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry.
ERA-EDTA Registry
extended-hours
haemodialysis
nocturnal haemodialysis
survival
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
28
06
2019
accepted:
13
09
2019
pubmed:
20
11
2019
medline:
18
9
2020
entrez:
20
11
2019
Statut:
ppublish
Résumé
Previous US studies have indicated that haemodialysis with ≥6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients. We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association-European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5-4 h/treatment), EHD (three times weekly, ≥6 h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders. From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.1 ± 0.8 h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 ± 0.2 h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62-0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71-0.90)]. EHD is associated with better survival in European patients treated with haemodialysis three times weekly.
Sections du résumé
BACKGROUND
Previous US studies have indicated that haemodialysis with ≥6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients.
METHODS
We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association-European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5-4 h/treatment), EHD (three times weekly, ≥6 h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders.
RESULTS
From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.1 ± 0.8 h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 ± 0.2 h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62-0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71-0.90)].
CONCLUSIONS
EHD is associated with better survival in European patients treated with haemodialysis three times weekly.
Identifiants
pubmed: 31740955
pii: 5628308
doi: 10.1093/ndt/gfz208
pmc: PMC7056951
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
488-495Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
Références
JAMA. 2007 Sep 19;298(11):1291-9
pubmed: 17878421
Nephrol Dial Transplant. 2001 Jun;16(6):1120-9
pubmed: 11390709
Kidney Int. 2006 Apr;69(7):1222-8
pubmed: 16609686
Clin Nephrol. 2006 Dec;66(6):433-9
pubmed: 17176915
Am J Kidney Dis. 2015 Sep;66(3):459-68
pubmed: 25863828
J Am Soc Nephrol. 2017 Jun;28(6):1898-1911
pubmed: 28151412
Miner Electrolyte Metab. 1999 Jul-Dec;25(4-6):391-6
pubmed: 10681672
Kidney Int. 2003 Dec;64(6):2222-8
pubmed: 14633146
J Am Coll Cardiol. 2002 Feb 20;39(4):695-701
pubmed: 11849871
JAMA. 2009 Oct 28;302(16):1782-9
pubmed: 19861670
Am J Kidney Dis. 2017 Aug;70(2):218-234
pubmed: 28359656
Clin J Am Soc Nephrol. 2010 Feb;5(2):220-6
pubmed: 19965529
Am J Kidney Dis. 2016 Apr;67(4):617-28
pubmed: 26561355
Nephrol Dial Transplant. 2012 Nov;27(11):4180-8
pubmed: 22431708
Heart. 2013 Mar;99(6):365-72
pubmed: 23118349
Am J Kidney Dis. 2014 Aug;64(2):247-56
pubmed: 24698199
Nephrol Dial Transplant. 2015 Jun;30(6):1028-37
pubmed: 25637641
J Am Soc Nephrol. 2012 Apr;23(4):696-705
pubmed: 22362910
Kidney Int. 2011 Nov;80(10):1080-91
pubmed: 21775973
Comput Methods Programs Biomed. 2004 Jul;75(1):45-9
pubmed: 15158046
Can J Cardiol. 2016 Mar;32(3):369-77
pubmed: 26386732
Circ J. 2014;78(10):2339-46
pubmed: 25077548
Kidney Int. 2009 Nov;76(9):984-90
pubmed: 19692997
Nephrol Dial Transplant. 2011 Apr;26(4):1287-96
pubmed: 21148270
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii60-ii67
pubmed: 28057870
J Am Soc Nephrol. 2013 Feb;24(3):498-505
pubmed: 23393319
Am J Kidney Dis. 2018 Apr;71(4):469-478
pubmed: 29198387
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii84-ii90
pubmed: 28201767
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
Kidney Int. 2016 Dec;90(6):1312-1320
pubmed: 27555118
J Am Soc Nephrol. 2012 Apr;23(4):687-95
pubmed: 22362905
Kidney Int. 2018 Jan;93(1):188-194
pubmed: 28844317
Nephrol Dial Transplant. 2019 Sep 1;34(9):1577-1584
pubmed: 30820580
Clin J Am Soc Nephrol. 2009 Dec;4(12):1925-31
pubmed: 19808220
Kidney Int. 2014 Jan;85(1):158-65
pubmed: 23802192
Clin Kidney J. 2018 Feb;11(1):108-122
pubmed: 29423210
Nephrol Dial Transplant. 2016 Jun;31(6):978-84
pubmed: 26492924
Hemodial Int. 2011 Apr;15(2):200-10
pubmed: 21395972
Toxins (Basel). 2016 Dec 08;8(12):
pubmed: 27941640